PharmExec Blog

Every Tenth New European Drug Developed in Finland

The number of drugs developed in Turku, Finland and granted marketing authorizations this year now stands at three, with a fourth expected to follow.
The FDA has granted market authorization for the IUD Skyla, developed by Bayer and intended for women who have not given birth, and Hormos Medical’s Ophena for postmenopausal symptoms. The European Medicine Agency has authorized of Selincro, a Biotie drug intended for the treatment of alcohol addiction.
Only about 30 new drugs receive marketing authorization in Europe each year, making theTurku turnout even more significant.
Read the full release here.

The number of drugs developed in Turku, Finland, and granted marketing authorizations this year now stands at three, with a fourth expected to follow.

The FDA granted market authorization for the IUD Skyla, developed by Bayer and intended for women who have not given birth, and Hormos Medical’s Ophena for postmenopausal symptoms. The European MedicinesAgency authorized Selincro, a Biotie drug intended for the treatment of alcohol addiction.

Only about 30 new drugs receive marketing authorization in Europe each year, making the Turku turnout even more remarkable.

Further information here.

This entry was posted in Europe, Global and tagged , , , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta